| TTFs | Tumor-treating fields |
| HGG | High-grade glioma |
| FDA | Food and Drug Administration |
| GBM | Glioblastoma multiforme |
| CNS | Central nervous system |
| DNA | Deoxyribonucleic acid |
| WHO | World Health Organization |
| TM | Trademark |
| PFS | Progression-free survival |
| OS | Overall survival |
| QoL | Quality of life |
| MRI | Magnetic resonance imaging |
| RANO | Response Assessment in Neuro-Oncology |
| MHLW | Ministry of Health Labour and Welfare |
| DMC | Data monitoring committee |
| RIG | Radiation-induced glioma |
| IDH | Isocitrate dehydrogenase |
| XRT | X-ray radiotherapy |
| mo | Months |
| Gy | Gray |
| CBTRUS | Central Brain Tumor Registry of the United States |
| GC | Gliomatosis cerebri |
| DMG | Diffuse midline glioma |
| PMDA | Pharmaceutics and Medical Devices Agency |
| USA | United States of America |
| HUMC | Hackensack University Medical Center |
| PBTC | Pediatric Brain Tumor Consortium |